he central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.
Forward-Looking Statements Page: 1 2 3 Related biology technology :1
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding when it will announce data from its Phase 1 clinical trial evaluating OMS824 as well as its two ongoing Phase 3 clinical programs; the number of preclinical programs that may enter the clinic in 2013; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2012. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking stat
. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference2
. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs3
. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs4
. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs5
. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year6
. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors7
. Synthetic Biologics Announces $10.8 Million Financing8
. Haemonetics Reports Second Quarter Fiscal 2013 Revenue Up 22%, Organic Revenue Up 6% and Adjusted EPS of $0.90, Reaffirms Fiscal 2013 Guidance and Announces Two-For-One Stock Split9
. Altogen Labs Announces Patent Filing for Bioremediation Process and Oil Spill Cleanup Products10
. Techne Corporation Declares Dividend And Announces An Increase In Its Share Repurchase Program11
. Law Office of Brodsky & Smith, LLC Announces Investigation of Complete Genomics, Inc.